Takao Watanabe1, Yoshio Tokumoto2, Kouji Joko3, Kojiro Michitaka4, Toshie Mashiba5, Atsushi Hiraoka6, Hironori Ochi7, Yohei Koizumi8, Fujimasa Tada9, Masashi Hirooka10, Osamu Yoshida11, Yusuke Imai12, Masanori Abe13, Yoichi Hiasa14. 1. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan. t_watanabe0303@yahoo.co.jp. 2. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan. yotoku@m.ehime-u.ac.jp. 3. Center for Liver-Biliary-Pancreatic Diseases, Matsuyama Red Cross Hospital, Bunkyocho 1, Matsuyama, Ehime, 790-8524, Japan. koujijoko@matsuyama.jrc.or.jp. 4. Department of Gastroenterology, Ehime Prefectural Central Hospital, Kasugamachi 83, Matsuyama, Ehime, 790-0024, Japan. kojiromichitaka@gmail.com. 5. Center for Liver-Biliary-Pancreatic Diseases, Matsuyama Red Cross Hospital, Bunkyocho 1, Matsuyama, Ehime, 790-8524, Japan. matoshi@matsuyama.jrc.or.jp. 6. Department of Gastroenterology, Ehime Prefectural Central Hospital, Kasugamachi 83, Matsuyama, Ehime, 790-0024, Japan. hirage@gmail.com. 7. Center for Liver-Biliary-Pancreatic Diseases, Matsuyama Red Cross Hospital, Bunkyocho 1, Matsuyama, Ehime, 790-8524, Japan. hironori@m.ehime-u.ac.jp. 8. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan. ykoizumi@m.ehime-u.ac.jp. 9. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan. fuji0227@m.ehime-u.ac.jp. 10. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan. masashih@m.ehime-u.ac.jp. 11. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan. yoshidao@m.ehime-u.ac.jp. 12. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan. yskyskimai@yahoo.co.jp. 13. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan. masaben@m.ehime-u.ac.jp. 14. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan. hiasa@m.ehime-u.ac.jp.
Abstract
BACKGROUND AND AIM: Entecavir is one of the most-used nucleoside analogues for the treatment of patients with chronic hepatitis B virus (HBV) infection. The aim of this study was to clarify the effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma (HCC). METHODS: The participants were 249 patients with chronic HBV infection who had been treated by entecavir for more than 2 years. Hepatic functional reserve and incidence of HCC were evaluated, and the factors that might contribute to the development of HCC were analyzed. RESULTS: Prothrombin activity was significantly elevated at 60 months after starting entecavir (from 85.9 ± 17.4 to 97.0 ± 16.9%, p < 0.001). The albumin level was also significantly elevated at 60 months after starting entecavir (from 4.0 ± 0.5 to 4.3 ± 0.3 mg/dL, p < 0.001). The annual incidence of HCC decreased over time, and the incidence of HCC was only 1.8% at 5 years after starting entecavir. On multivariate analysis for HCC incidence, older age and low platelet count were significant, independent contributing factors. CONCLUSIONS: Long-term treatment with entecavir improved hepatic functional reserve and decreased the incidence of HCC over time after 3 years. To decrease the incidence of HCC, careful induction of long-term entecavir treatment in younger patients with chronic HBV infection and better hepatic functional reserve would be important.
BACKGROUND AND AIM: Entecavir is one of the most-used nucleoside analogues for the treatment of patients with chronic hepatitis B virus (HBV) infection. The aim of this study was to clarify the effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma (HCC). METHODS: The participants were 249 patients with chronic HBV infection who had been treated by entecavir for more than 2 years. Hepatic functional reserve and incidence of HCC were evaluated, and the factors that might contribute to the development of HCC were analyzed. RESULTS:Prothrombin activity was significantly elevated at 60 months after starting entecavir (from 85.9 ± 17.4 to 97.0 ± 16.9%, p < 0.001). The albumin level was also significantly elevated at 60 months after starting entecavir (from 4.0 ± 0.5 to 4.3 ± 0.3 mg/dL, p < 0.001). The annual incidence of HCC decreased over time, and the incidence of HCC was only 1.8% at 5 years after starting entecavir. On multivariate analysis for HCC incidence, older age and low platelet count were significant, independent contributing factors. CONCLUSIONS: Long-term treatment with entecavir improved hepatic functional reserve and decreased the incidence of HCC over time after 3 years. To decrease the incidence of HCC, careful induction of long-term entecavir treatment in younger patients with chronic HBV infection and better hepatic functional reserve would be important.
Authors: Beom Kyung Kim; Jun Yong Park; Do Young Kim; Ja Kyung Kim; Kyung Sik Kim; Jin Sub Choi; Byung Soo Moon; Kwang Hyub Han; Chae Yoon Chon; Young Myoung Moon; Sang Hoon Ahn Journal: Liver Int Date: 2007-11-19 Impact factor: 5.828
Authors: Man-Fung Yuen; Wai-Kay Seto; Danny Hoi-Fan Chow; Kit Tsui; Danny Ka-Ho Wong; Vincent Wing-Shun Ngai; Benjamin Chun-Yu Wong; James Fung; John Chi-Hang Yuen; Ching-Lung Lai Journal: Antivir Ther Date: 2007